近日,美国临床试验收录网显示,百时美施贵宝(BMS)的 CD19 CAR-T 细胞疗法 Zola-cel启动了首个 Ⅲ 期临床试验,治疗活动性系统性硬化症(SSc)。Zola-cel是BMS基于NEX-T平台开发的一款CD19 CAR-T细胞疗法,于2020年进入临床阶段。截至目前,该药物已在系统性红斑狼疮、特发性炎症性肌病、系统性硬化症(SSc)和多发性硬化症人群中完成I期验证。Zola-cel...
Source Link近日,美国临床试验收录网显示,百时美施贵宝(BMS)的 CD19 CAR-T 细胞疗法 Zola-cel启动了首个 Ⅲ 期临床试验,治疗活动性系统性硬化症(SSc)。Zola-cel是BMS基于NEX-T平台开发的一款CD19 CAR-T细胞疗法,于2020年进入临床阶段。截至目前,该药物已在系统性红斑狼疮、特发性炎症性肌病、系统性硬化症(SSc)和多发性硬化症人群中完成I期验证。Zola-cel...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.